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background
 
Glioblastoma, the most common primary brain tumor in adults, is usually rapidly fatal.
The current standard of care for newly diagnosed glioblastoma is surgical resection to
the extent feasible, followed by adjuvant radiotherapy. In this trial we compared radio-
therapy alone with radiotherapy plus temozolomide, given concomitantly with and after
radiotherapy, in terms of efficacy and safety.
 
methods
 
Patients with newly diagnosed, histologically confirmed glioblastoma were randomly
assigned to receive radiotherapy alone (fractionated focal irradiation in daily fractions of
2 Gy given 5 days per week for 6 weeks, for a total of 60 Gy) or radiotherapy plus contin-
uous daily temozolomide (75 mg per square meter of body-surface area per day, 7 days
per week from the first to the last day of radiotherapy), followed by six cycles of adju-
vant temozolomide (150 to 200 mg per square meter for 5 days during each 28-day
cycle). The primary end point was overall survival.
 
results
 
A total of 573 patients from 85 centers underwent randomization. The median age was
56 years, and 84 percent of patients had undergone debulking surgery. At a median fol-
low-up of 28 months, the median survival was 14.6 months with radiotherapy plus
temozolomide and 12.1 months with radiotherapy alone. The unadjusted hazard ratio
for death in the radiotherapy-plus-temozolomide group was 0.63 (95 percent confidence
interval, 0.52 to 0.75; P<0.001 by the log-rank test). The two-year survival rate was
26.5 percent with radiotherapy plus temozolomide and 10.4 percent with radiotherapy
alone. Concomitant treatment with radiotherapy plus temozolomide resulted in grade 3
or 4 hematologic toxic effects in 7 percent of patients.
 
conclusions
 
The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma result-
ed in a clinically meaningful and statistically significant survival benefit with minimal
additional toxicity.
abstract
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lioblastoma is the most frequent
 
primary malignant brain tumor in adults.
Median survival is generally less than one
year from the time of diagnosis, and even in the
most favorable situations, most patients die within
two years.
 
1-3
 
 Standard therapy consists of surgical
resection to the extent that is safely feasible, fol-
lowed by radiotherapy; in the United States, adju-
vant carmustine, a nitrosourea drug, is commonly
prescribed.
 
4,5
 
 Cooperative-group trials have inves-
tigated the addition of various chemotherapeutic
regimens to radiotherapy,
 
6-9
 
 but no randomized
phase 3 trial of nitrosourea-based adjuvant chemo-
therapy has demonstrated a significant survival ben-
efit as compared with radiotherapy alone, although
there were more long-term survivors in the chemo-
therapy groups in some studies.
 
10 
 
A meta-analysis
based on 12 randomized trials suggested a small
survival benefit of chemotherapy, as compared
with radiotherapy alone (a 5 percent increase in
survival at two years, from 15 percent to 20 per-
cent).
 
11 
 
The meta-analysis included 37 percent of
patients with prognostically more favorable, lower-
grade gliomas.
Temozolomide, an oral alkylating agent, has
demonstrated antitumor  activity as a single agent
in the treatment of recurrent glioma.
 
12-14
 
 The ap-
proved conventional schedule is a daily dose of 150
to 200 mg per square meter of body-surface area for
5 days of every 28-day cycle. Daily therapy at a dose
of 75 mg per square meter for up to seven weeks is
safe; this level of exposure to temozolomide
 
15
 
 de-
pletes the DNA-repair enzyme O
 
6
 
-methylguanine-
DNA methyltransferase (MGMT).
 
16
 
 This effect may
be important because low levels of MGMT in tumor
tissue are associated with longer survival among pa-
tients with glioblastoma who are receiving nitroso-
urea-based adjuvant chemotherapy.
 
17,18
 
A pilot phase 2 trial demonstrated the feasibility
of the concomitant administration of temozolo-
mide with fractionated radiotherapy, followed by up
to six cycles of adjuvant temozolomide, and suggest-
ed that this treatment had promising clinical activ-
ity (two-year survival rate, 31 percent).
 
19 
 
The Euro-
pean Organisation for Research and Treatment of
Cancer (EORTC) Brain Tumor and Radiotherapy
Groups and the National Cancer Institute of Canada
(NCIC) Clinical Trials Group therefore initiated a
randomized, multicenter, phase 3 trial to compare
this regimen with radiotherapy alone in patients
with newly diagnosed glioblastoma.
 
patients
 
Patients 18 to 70 years of age with newly diagnosed
and histologically confirmed glioblastoma (World
Health Organization [WHO] grade IV astrocytoma)
were eligible for the study. Eligible patients had a
WHO performance status of 2 or less and adequate
hematologic, renal, and hepatic function (absolute
neutrophil count, ≥1500 per cubic millimeter; plate-
let count, ≥100,000 per cubic millimeter; serum cre-
atinine level, ≤1.5 times the upper limit of normal
in the laboratory where it was measured; total se-
rum bilirubin level, ≤1.5 times the upper limit of
normal; and liver-function values, <3 times the up-
per limit of normal for the laboratory). Patients who
were receiving corticosteroids had to receive a stable
or decreasing dose for at least 14 days before ran-
domization. All patients provided written informed
consent, and the study was approved by the ethics
committees of the participating centers. 
 
study design and treatment
 
Within six weeks after the histologic diagnosis of
glioblastoma, we randomly assigned eligible pa-
tients to receive standard focal radiotherapy alone
(the control group) or standard radiotherapy plus
concomitant daily temozolomide, followed by adju-
vant temozolomide. Randomization was performed
at the EORTC Data Center, and patients were strat-
ified according to WHO performance status, wheth-
er or not they had previously undergone debulking
surgery, and the treatment center.
 
20
 
 The assigned
treatment had to begin within one week after ran-
domization.
Radiotherapy consisted of fractionated focal ir-
radiation at a dose of 2 Gy per fraction given once
daily five days per week (Monday through Friday)
over a period of six weeks, for a total dose of 60 Gy.
Radiotherapy was delivered to the gross tumor vol-
ume with a 2-to-3-cm margin for the clinical target
volume. Radiotherapy was planned with dedicated
computed tomography (CT) and three-dimensional
planning systems; conformal radiotherapy was de-
livered with linear accelerators with nominal energy
of 6 MV or more, and quality assurance was per-
formed by means of individual case reviews.
 
21
 
 
Concomitant chemotherapy consisted of tem-
ozolomide (marketed as Temodal in Europe and
Canada and Temodar in the United States; Scher-
ing-Plough) at a dose of 75 mg per square meter per
g methods
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day, given 7 days per week from the first day of ra-
diotherapy until the last day of radiotherapy, but for
no longer than 49 days. After a 4-week break, pa-
tients were then to receive up to six cycles of adju-
vant temozolomide according to the standard 5-day
schedule every 28 days. The dose was 150 mg per
square meter for the first cycle and was increased to
200 mg per square meter beginning with the second
cycle, so long as there were no hematologic toxic ef-
fects. Because continuous daily temozolomide can
cause lymphocytopenia, with a possible increased
risk of opportunistic infections, patients in the ra-
diotherapy-plus-temozolomide group were to re-
ceive prophylaxis against 
 
Pneumocystis carinii
 
 pneu-
monia, consisting of either inhaled pentamidine
or oral trimethoprim–sulfamethoxazole,
 
22
 
 during
concomitant treatment with radiotherapy plus tem-
ozolomide. Antiemetic prophylaxis with metoclo-
pramide or a 5-hydroxytryptamine
 
3
 
 antagonist was
recommended before the initial doses of concomi-
tant temozolomide and was required during the ad-
juvant five-day courses of temozolomide.
 
surveillance and follow-up
 
The baseline examination included CT or magnetic
resonance imaging (MRI), full blood counts and
blood chemistry tests, and a physical examination
that included the Mini–Mental State Examination
(MMSE) and a quality-of-life questionnaire. During
radiotherapy (with or without temozolomide), pa-
tients were to be seen every week. Twenty-one to 28
days after the completion of radiotherapy and every
3 months thereafter, patients underwent a compre-
hensive evaluation, including administration of the
MMSE and the quality-of-life questionnaire and
radiologic assessment of the tumor. During adju-
vant temozolomide therapy, patients underwent a
monthly clinical evaluation and a comprehensive
evaluation at the end of cycles 3 and 6. Tumor pro-
gression was defined according to the modified
WHO criteria as an increase in tumor size by 25 per-
cent, the appearance of new lesions, or an increased
need for corticosteroids.
 
23
 
 When there was tumor
progression or after two years of follow-up, patients
were treated at the investigator’s discretion, and the
type of second-line therapy was recorded. Toxic ef-
fects were graded according to the National Cancer
Institute Common Toxicity Criteria, version 2.0,
with a score of 1 indicating mild adverse effects, a
score of 2 moderate adverse effects, a score of 3 se-
vere adverse effects, and a score of 4 life-threatening
adverse effects. 
 
statistical analysis
 
The primary end point was overall survival; second-
ary end points were progression-free survival, safety,
and the quality of life. Overall survival and pro-
gression-free survival were analyzed by the Kaplan–
Meier method, with use of two-sided log-rank
statistics. This study had 80 percent power at a sig-
nificance level of 0.05 to detect a 33 percent in-
crease in median survival (hazard ratio for death,
0.75), assuming that 382 deaths occurred. All analy-
ses were conducted on an intention-to-treat basis.
The Cox proportional-hazards model was fitted to
adjust for stratification factors and other confound-
ing variables. Toxic effects are reported separately
for the radiotherapy period, defined as extending
from day 1 of radiotherapy until 28 days after the
last day of radiotherapy, or until the first day of ad-
juvant temozolomide therapy. The adjuvant-therapy
period was defined as extending from the first day
of adjuvant temozolomide therapy until 35 days
after day 1 of the last cycle of temozolomide. Find-
ings with respect to the quality of life are not re-
ported here.
 
organization of the trial
 
The concept of the trial was developed by Dr. Stupp
in collaboration with the EORTC Data Center, the
EORTC Brain Tumor and Radiotherapy Groups,
and the NCIC Clinical Trials Group, represented by
Drs. Cairncross and Eisenhauer. The radiotherapy
design and quality assurance were supervised by
Dr. Mirimanoff. The trial was sponsored by the
EORTC Brain Tumor and Radiotherapy Groups
(trial 22981/26981) in Europe and the NCIC Clini-
cal Trials Group (trial CE.3) in Canada. The trial was
supported by an unrestricted educational grant
from Schering-Plough, which also provided the
study drug; however, Schering-Plough was not in-
volved in trial design or analysis. All data were col-
lected by the EORTC and NCIC data centers and re-
viewed by Drs. Stupp and Mirimanoff. The analysis
was performed by the EORTC statistician, Mr. Gor-
lia. Histologic specimens were reviewed centrally
(according to the revised WHO classification sys-
tem
 
24
 
) by a panel of three neuropathologists in Eu-
rope (Robert C. Janzer in Lausanne, Switzerland
[chair]; Peter Wesseling in Nijmegen, the Nether-
lands; and Karima Mohktari in Paris) and a single
neuropathologist in Canada (Samuel Ludwin, King-
ston, Ont.). The article was written by Dr. Stupp with
support from a medical writer and coauthors; all au-
thors reviewed the manuscript.
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patients
 
From August 2000 until March 2002, 573 patients
from 85 institutions in 15 countries were randomly
assigned to receive radiotherapy (286 patients) or
radiotherapy plus temozolomide (287 patients).
Nearly 50 percent of the patients were enrolled at
17 institutions. The characteristics of the patients
in the two groups were well balanced at baseline
(Table 1). The median age was 56 years, and 84 per-
cent of patients had undergone debulking surgery.
Slightly more patients in the radiotherapy group
than in the radiotherapy-plus-temozolomide group
were receiving corticosteroids at the time of ran-
domization (75 percent vs. 67 percent). Histologic
slides were submitted for 85 percent of patients,
and central pathological review confirmed the diag-
nosis of glioblastoma in 93 percent of the reviewed
cases; 3 percent had anaplastic astrocytoma or oli-
goastrocytoma (WHO grade III), and in 1 percent
submitted material was insufficient for a definitive
diagnosis.
 
disposition of patients and delivery 
of treatment
 
The median time from diagnosis to the start of ther-
apy was 5 weeks (range, 2.0 to 12.9) in the radio-
therapy group and 5 weeks (range, 1.7 to 10.7) in
the radiotherapy-plus-temozolomide group. Table 2
summarizes the details of treatment. Unplanned
interruptions in radiotherapy were usually brief
(median, four days) and interruptions due to the
toxicity of therapy occurred in only 3 percent of the
radiotherapy group and 4 percent of the radiother-
apy-plus-temozolomide group. The other reasons
were mainly administrative (e.g., holidays, radio-
therapy equipment maintenance, or technical prob-
lems). One patient randomly assigned to radiother-
apy alone received radiotherapy plus temozolomide.
Among the 287 patients who were assigned to re-
ceive concomitant radiotherapy plus temozolo-
mide, 85 percent completed both radiotherapy and
temozolomide as planned. Thirty-seven patients
(13 percent) prematurely discontinued temozolo-
mide because of toxic effects (in 14 patients), dis-
ease progression (in 11), or other reasons (in 12).
After radiotherapy, 223 patients in the radio-
therapy-plus-temozolomide group (78 percent)
started adjuvant temozolomide and received a me-
dian of 3 cycles (range, 0 to 7); 47 percent of pa-
tients completed 6 cycles. The main reason for not
results
 
* This characteristic was used as a stratification factor at the time of random-
ization.
† A performance status of 0 denotes asymptomatic, 1 symptomatic and fully 
ambulatory, and 2 symptomatic and in bed less than 50 percent of the day.
‡ The maximum score on the Mini–Mental State Examination (MMSE) is 30, 
and scores above 26 are considered to indicate normal mental status.
 
§ Anaplastic astrocytoma included oligoastrocytoma.
 
Table 1. Demographic Characteristics of the Patients at Baseline.
Characteristic
Radiotherapy 
(N=286)
Radiotherapy 
plus Temozolo-
mide (N=287)
 
Age — yr
Median 57 56
Range 23–71 19–70
Age — no. (%)*
<50 yr 81 (28) 90 (31)
≥50 yr 205 (72) 197 (69)
Sex — no. (%)
Male 175 (61) 185 (64)
Female 111 (39) 102 (36)
WHO performance status — no. (%)*†
0 110 (38) 113 (39)
1 141 (49) 136 (47)
2 35 (12)  38 (13)
Extent of surgery — no. (%)*
Biopsy 45 (16) 48 (17)
Debulking 241 (84) 239 (83)
Complete resection 113 (40) 113 (39)
Partial resection 128 (45) 126 (44)
Time from diagnosis to radiotherapy — wk
Median 5 5
Range 2.0–12.9 1.7–10.7
Baseline MMSE score — no. (%)‡
30 91 (32) 100 (35)
27–29 97 (34) 96 (33)
≤26 86 (30) 81 (28)
Data missing 12 (4) 10 (3)
Corticosteroid therapy — no. (%)
Yes 215 (75) 193 (67)
No 70 (24) 94 (33)
Data missing 1 (<1) 0
Slides available for pathological review
— no. (%)
246 (86) 239 (83)
Findings on pathological review — no. (%)
Glioblastoma 229 (93) 221 (92)
Anaplastic astrocytoma§ 9 (4) 7 (3)
Inconclusive material 3 (1) 3 (1)
Other 5 (2) 8 (3)
The New England Journal of Medicine 
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* Other reasons included any missed dose or patient or prescription error.
 
Table 2. Disposition of Patients and Intensity of Treatment.
Variable Radiotherapy (N=286) Radiotherapy plus Temozolomide (N=287)
Radiotherapy
 
Never started radiotherapy — no. (%) 7 (2) 3 (1)
Dose — Gy  
Median 60 60
Range 12–62 12–62
No. of fractions
Median 30 30
Range 6–33  5–33
Duration — wk  
Median 6.1 6.0
Range  1.3–7.6 0.6–10.3
Interruption or delay in radiotherapy — no. (%) 78 (27) 92 (32)
Delay due to toxicity — no. (%) 8 (3) 12 (4)
Received ≤90% of planned dose — no. (%) 22 (8) 14 (5)
Early discontinuation of radiotherapy — no. (%) 19 (7) 14 (5)
Reason for discontinuation — no. (%)
Disease progression 17 (6) 11 (4)
Other* 2 (1) 3 (1)
 
Concomitant temozolomide
 
Never started concomitant temozolomide — no. (%) — 6 (2)
Duration of therapy — days
Median — 42
Range —  40–55
Received ≤90% of planned dose — no. (%) — 23 (8)
Early discontinuation of concomitant temozolomide — no. (%) — 37 (13)
Reason for discontinuation of temozolomide — no. (%)
Toxic effects — 14 (5)
Disease progression — 11 (4)
Other* — 12 (4)
 
Adjuvant-therapy period
 
Adjuvant temozolomide started — no. (%) 223 (78)
Cycles of temozolomide 
Median — 3
Range — 0–7
Patients completing 6 cycles — no. (%) — 105 (47)
Dose escalated to 200 mg/m
 
2
 
 at cycle 2 — no. (%) — 149 (67)
Adjuvant temozolomide discontinued — no. (%) 118 (53)
Reason for discontinuation — no. (%)
Disease progression — 86 (39)
Toxic effects — 17 (8)
Decision by patient — 8 (4)
Other — 6 (3)
Missing data — 1 (<1)
The New England Journal of Medicine 
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beginning or not completing adjuvant temozolo-
mide therapy was disease progression. Only 8 per-
cent of patients discontinued adjuvant temozolo-
mide because of toxic effects. Beginning with cycle
2, the dose of temozolomide was increased to 200
mg per square meter in 67 percent of patients. Only
9 percent of patients did not receive the higher dose
because of hematologic toxicity.
 
survival and progression
 
At a median follow-up of 28 months, 480 patients
(84 percent) had died. The unadjusted hazard ratio
for death in the radiotherapy-plus-temozolomide
group as compared with the radiotherapy group was
0.63 (95 percent confidence interval, 0.52 to 0.75;
P<0.001 by the log-rank test). These data indicate a
37 percent relative reduction in the risk of death for
patients treated with radiotherapy plus temozolo-
mide, as compared with those who received radio-
therapy alone.
The median survival benefit was 2.5 months; the
median survival was 14.6 months (95 percent con-
fidence interval, 13.2 to 16.8) with radiotherapy plus
temozolomide and 12.1 months (95 percent confi-
dence interval, 11.2 to 13.0) with radiotherapy alone
(Fig. 1 and Table 3). The two-year survival rate was
26.5 percent (95 percent confidence interval, 21.2
to 31.7 percent) in the group given radiotherapy
plus temozolomide, as compared with 10.4 percent
(95 percent confidence interval, 6.8 to 14.1 percent)
with radiotherapy alone. The median progression-
free survival was 6.9 months (95 percent confidence
interval, 5.8 to 8.2) with radiotherapy plus temozo-
lomide and 5.0 months (95 percent confidence in-
terval, 4.2 to 5.5) with radiotherapy alone (hazard
ratio for death or disease progression, 0.54 [95 per-
cent confidence interval, 0.45 to 0.64]; P<0.001 by
the log-rank test) (Fig. 2).
The hazard ratio for death was adjusted by fitting
the Cox proportional-hazard models. In addition
to the stratification factors (the extent of surgery,
WHO performance status, and treatment center),
other possible confounding factors — age, use or
nonuse of corticosteroids at randomization, sex,
score on the MMSE, and tumor location — were in-
cluded. The adjusted hazard ratio for death in the
radiotherapy-plus-temozolomide group as com-
pared with the radiotherapy group — 0.62 (95 per-
cent confidence interval, 0.51 to 0.75) — was es-
sentially the same as the unadjusted hazard ratio.
Survival according to prognostic factors, includ-
ing age, sex, extent of surgery, WHO performance
status, and use or nonuse of corticosteroids, was
also analyzed (see Table 1 in the Supplementary Ap-
pendix, available with the full text of this article at
www.nejm.org). Radiotherapy plus temozolomide
was associated with a significant improvement in
median overall survival in nearly all subgroups of
patients (see Fig. 1 in the Supplementary Appen-
dix); the exceptions were the small subgroup of 93
patients who underwent biopsy only and the 70 pa-
tients with a poor performance status.
 
safety
 
We analyzed adverse events separately during radio-
therapy (with or without concomitant temozolo-
mide), the adjuvant-therapy period, and the entire
study period (from study entry until disease progres-
sion or last follow-up). No grade 3 or 4 hematologic
toxic effects were observed in the radiotherapy
group. During concomitant temozolomide thera-
py, grade 3 or 4 neutropenia was documented in 12
patients (4 percent), and grade 3 or 4 thrombocyto-
penia occurred in 9 patients (3 percent) (Table 4).
Overall, 19 patients (7 percent) had any type of
grade 3 or 4 hematologic toxic effect. During adju-
vant temozolomide therapy, 14 percent of patients
 
Figure 1. Kaplan–Meier Estimates of Overall Survival According to 
Treatment Group.
 
The hazard ratio for death among patients treated with radiotherapy plus temo-
zolomide, as compared with those who received radiotherapy alone, was 0.63 
(95 percent confidence interval, 0.52 to 0.75; P<0.001).
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had any grade 3 or 4 hematologic toxic effect, 4 per-
cent had grade 3 or 4 neutropenia, and 11 percent
had grade 3 or 4 thrombocytopenia.
 During the radiotherapy period, severe infec-
tions occurred in 6 patients in the radiotherapy
group (2 percent) and in 9 patients in the radiother-
apy-plus-temozolomide group (3 percent); during
adjuvant temozolomide therapy, 12 patients (5 per-
cent) had severe infections. The most common non-
hematologic adverse event during radiotherapy was
moderate-to-severe fatigue in 26 percent of patients
in the radiotherapy group and 33 percent in the ra-
diotherapy-plus-temozolomide group (Table 2 in
the Supplementary Appendix). Thromboembolic
events occurred in 28 patients (5 percent) — 16 in
the radiotherapy group and 12 in the radiotherapy-
plus-temozolomide group. Two patients in the ra-
diotherapy-plus-temozolomide group died of cere-
bral hemorrhage in the absence of a coagulation
disorder or thrombocytopenia. Pneumonia was re-
ported in five patients in the radiotherapy group
and three in the radiotherapy-plus-temozolomide
group. Opportunistic infections occurred in two pa-
tients; one patient treated with radiotherapy alone
had suspected 
 
P. carinii
 
 pneumonia, and one patient
in the radiotherapy-plus-temozolomide group had
proven bacterial and candida pneumonia.
 
treatment after disease progression
 
If disease progression occurred, further treatment
was at the physician’s discretion. At the cutoff date
(May 10, 2004), 512 patients — 268 in the radiother-
apy group (94 percent) and 244 in the radiotherapy-
plus-temozolomide group (85 percent) — had dis-
ease progression. At the time of progression, 23
percent of patients in both treatment groups under-
went a second surgery, and 72 percent of patients
in the radiotherapy group and 58 percent in the ra-
diotherapy-plus-temozolomide group received che-
motherapy. Salvage chemotherapy consisted of
temozolomide in 60 percent of patients in the ra-
diotherapy group and 25 percent of patients in the
radiotherapy-plus-temozolomide group. The re-
sponse to salvage chemotherapy was not recorded
as part of our study.
For more than 30 years, chemotherapy given as an
adjunct to radiotherapy or before radiotherapy has
been widely investigated in patients with malig-
nant glioma. Such treatment has had limited suc-
cess.
 
6-8,10,25-27
 
 The present study demonstrates
that the addition of chemotherapy to radiotherapy
significantly prolongs survival among patients with
newly diagnosed glioblastoma, with a median in-
crease in survival of 2.5 months or a relative reduc-
tion in the risk of death of 37 percent. Unlike most
previous studies, which included patients with both
glioblastoma (WHO grade IV) and anaplastic astro-
cytoma (WHO grade III), who have a better prog-
nosis, our study was designed to include only pa-
tients with glioblastoma. At two years, we found a
clinically meaningful increase — by a factor of 2.5
— in the survival rate, from 10 percent with radio-
therapy alone to 27 percent with radiotherapy plus
temozolomide, consistent with the findings of the
preceding phase 2 trial.
 
19
 
 An exploratory analysis of
subgroups defined according to known prognostic
factors demonstrated a survival benefit in nearly all
subgroups.
The outcome for patients treated with radiother-
apy alone in our trial compares favorably with the
outcome in other trials.
 
9,11,28
 
 Patients being treated
with corticosteroids received stable or decreasing
doses before randomization and started radiother-
apy within one week after randomization. These cri-
discussion
 
* A total of 160 patients in the radiotherapy group and 60 patients in the radio-
therapy-plus-temozolomide group received temozolomide as salvage therapy. 
 
CIdenotes confidence interval. 
 
Table 3. Overall and Progression-free Survival According to Treatment Group.*
Variable
Radiotherapy
(N=286)
Radiotherapy 
plus Temozolomide
(N=287)
 
value (95% CI)
 
Median overall survival (mo) 12.1 (11.2–13.0) 14.6 (13.2–16.8)
Overall survival (%)
At 6 months 84.2 (80.0–88.5) 86.3 (82.3–90.3)
At 12 months 50.6 (44.7–56.4) 61.1 (55.4–66.7)
At 18 months 20.9 (16.2–26.6) 39.4 (33.8–45.1)
At 24 months 10.4 (6.8–14.1) 26.5 (21.2–31.7)
Median progression-free
survival (mo)
5.0 (4.2–5.5) 6.9 (5.8–8.2 )
Progression-free survival (%)
At 6 months 36.4 (30.8–41.9) 53.9 (48.1–59.6)
At 12 months 9.1 (5.8–12.4) 26.9 (21.8–32.1)
At 18 months 3.9 (1.6–6.1) 18.4 (13.9–22.9)
At 24 months 1.5 (0.1–3.0) 10.7 (7.0–14.3)
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teria may have served to exclude patients with the
worst prognosis, who may not benefit from any
therapy. Moreover, most patients had undergone
debulking surgery. The relatively long survival after
disease progression (approximately seven months
in both groups) is also noteworthy. This extended
survival may reflect either patient selection or the
early detection of tumor progression by means of
regular radiographic assessment. Furthermore, 72
percent of patients in the radiotherapy group and
58 percent of patients in the radiotherapy-plus-tem-
ozolomide group received salvage chemotherapy at
the time of progression.
This trial was designed to determine whether the
addition of temozolomide to radiotherapy early in
the course of treatment prolongs survival among
patients with glioblastoma, but it was not designed
to distinguish between the effects of concomitant
therapy with radiotherapy plus temozolomide and
adjuvant treatment with temozolomide. At the time
the trial was conceived, it was deemed most impor-
tant to administer chemotherapy early in the course
of the disease, for a sufficiently long time, and con-
currently with radiotherapy. Temozolomide was
given concomitantly with radiotherapy on a contin-
uous schedule for several reasons. First, daily ad-
ministration of low doses makes possible an in-
crease by almost a factor of two in dose intensity, as
compared with the standard regimen, without an
increase in toxicity.
 
15
 
 Second, continuous adminis-
tration of an alkylating agent depletes MGMT,
 
16
 
 an
enzyme that may be induced by radiotherapy and
that is necessary for repair of damage to DNA caused
by alkylating agents.
 
29
 
 In a companion translation-
al study also reported in this issue of the 
 
Journal,
 
 we
observed that methylation of the 
 
MGMT
 
 promoter,
which results in gene silencing, is associated with a
striking survival benefit in patients treated with ra-
diotherapy plus temozolomide.
 
30
 
 Third, synergy
between temozolomide and radiotherapy has been
observed in vitro.
 
31-33
 
 The spontaneous conversion
of temozolomide into the active metabolite and its
ability to cross the blood–brain barrier also favors
this regimen.
 
34
 
 Finally, to ensure sufficient exposure
to the drug, we added six cycles of adjuvant temo-
zolomide after the completion of radiotherapy.
In the context of palliative care, chemotherapy-
induced toxic effects should be manageable. Nau-
sea was controlled with standard antiemetic agents.
Severe myelosuppression was observed in 16 per-
cent of patients, leading to the early discontinuation
of chemotherapy in 5 percent. Whether the addition
of chemotherapy increases the risk of radiotherapy-
induced cognitive deficits cannot be assessed at this
time. However, long-term monitoring and observa-
tional studies of late toxic effects will be important
to guide treatment recommendations in the future.
Furthermore, prolonged chemotherapy with alkyl-
ating agents has been associated with myelodys-
plastic syndromes and secondary leukemia occur-
ring years after therapy.
 
35
 
 In our trial, at a median
 
Figure 2. Kaplan–Meier Estimates of Progression-free Survival According to 
Treatment Group.
 
The hazard ratio for death or disease progression among patients treated 
with radiotherapy plus temozolomide, as compared with those treated with 
radiotherapy alone, was 0.54 (95 percent confidence interval, 0.45 to 0.64; 
P<0.001).
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* The entire study period was defined as the period from study entry to seven 
 
days after disease progression.
 
Table 4. Grade 3 or 4 Hematologic Toxic Effects in Patients Treated
with Temozolomide.
Toxic Effect
Concomitant
Temozolomide 
Therapy
(N=284)
Adjuvant
Temozolomide 
Therapy 
(N=223)
Entire Study
Period*
(N=284)
 
number of patients (percent)
 
Leukopenia 7 (2) 11 (5) 20 (7)
Neutropenia 12 (4) 9 (4) 21 (7)
Thrombocytopenia 9 (3) 24 (11) 33 (12)
Anemia 1 (<1) 2 (1) 4 (1)
Any 19 (7) 32 (14) 46 (16)
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follow-up of approximately two years, there had
been no evidence of any increase in treatment-
induced late toxic effects. Such late toxicity may be-
come a greater concern, however, if this regimen is
used in patients with intermediate- or low-grade
glioma, who have a more favorable prognosis in
terms of survival.
In conclusion, the addition of temozolomide to
radiotherapy early in the course of glioblastoma pro-
vides a statistically significant and clinically mean-
ingful survival benefit. Nevertheless, the challenge
remains to improve clinical outcomes further. For
this reason, the regimen of radiotherapy plus tem-
ozolomide should serve as the new platform from
which to explore innovative regimens for treating
malignant gliomas. Many questions remain unan-
swered regarding the applications of this regimen
to lower grade gliomas and the optimal combina-
tion of radiotherapy and temozolomide.
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